Iron-substituted cobalt-free lithium-rich manganese-based materials,with advantages of high specific capacity,high safety,and low cost,have been considered as the potential cathodes for lithium ion batteries.However,c...Iron-substituted cobalt-free lithium-rich manganese-based materials,with advantages of high specific capacity,high safety,and low cost,have been considered as the potential cathodes for lithium ion batteries.However,challenges,such as poor cycle stability and fast voltage fade during cycling under high potential,hinder these materials from commercialization.Here,we developed a method to directly coat LiF on the particle surface of Li_(1.2)Ni_(0.15)Fe_(0.1)Mn_(0.55O2).A uniform and flat film was successfully formed with a thickness about 3 nm,which can effect-ively protect the cathode material from irreversible phase transition during the deintercalation of Li^(+).After surface coating with 0.5wt%LiF,the cycling stability of Li_(1.2)Ni_(0.15)Fe_(0.1)Mn_(0.55O2) cycled at high potential was significantly improved and the voltage fade was largely suppressed.展开更多
To the Editor:Umbilical cord blood transplant(UCBT)serves as an alternative option for treating patients with B cell acute lymphoblastic leukemia(ALL),in the absence of a compatible donor.However,disease recurrence pr...To the Editor:Umbilical cord blood transplant(UCBT)serves as an alternative option for treating patients with B cell acute lymphoblastic leukemia(ALL),in the absence of a compatible donor.However,disease recurrence presents a difficult challenge.Chimeric antigen receptor(CAR)-T cell therapy is a promising approach for treating patients with relapsed/refractory ALL.Among the intensive investigations of infusion of CAR-T cells after transplant,few focus on patients who were administered CAR-T therapy after they relapsed subsequently to UCBT.Here,we report the response rate,toxicity,and survival of CD19 CAR-T cells administered to 10 children and young adults with relapsed acute B lymphoblastic leukemia(B-ALL)after UCBT.Between April 2018 and September 2019,11 patients with relapsed B-ALL after UCBT were enrolled,including three females and eight males,the median age was 10 years(range 7-22 years)and median weight was 35.0 kg(range 21.0-72.0 kg).Patient 10 was excluded because of unsuccessful cell culture.展开更多
基金financially supported by the project of International Science&Technology Cooperation of China(No.2019YFE0100200)。
文摘Iron-substituted cobalt-free lithium-rich manganese-based materials,with advantages of high specific capacity,high safety,and low cost,have been considered as the potential cathodes for lithium ion batteries.However,challenges,such as poor cycle stability and fast voltage fade during cycling under high potential,hinder these materials from commercialization.Here,we developed a method to directly coat LiF on the particle surface of Li_(1.2)Ni_(0.15)Fe_(0.1)Mn_(0.55O2).A uniform and flat film was successfully formed with a thickness about 3 nm,which can effect-ively protect the cathode material from irreversible phase transition during the deintercalation of Li^(+).After surface coating with 0.5wt%LiF,the cycling stability of Li_(1.2)Ni_(0.15)Fe_(0.1)Mn_(0.55O2) cycled at high potential was significantly improved and the voltage fade was largely suppressed.
基金The work was supported by grants from the Science and Technology Planning Project of Anhui Province,China(No.1604a0802071)the Major Science and Technology Projects of Anhui Province,China(No.18030801126)。
文摘To the Editor:Umbilical cord blood transplant(UCBT)serves as an alternative option for treating patients with B cell acute lymphoblastic leukemia(ALL),in the absence of a compatible donor.However,disease recurrence presents a difficult challenge.Chimeric antigen receptor(CAR)-T cell therapy is a promising approach for treating patients with relapsed/refractory ALL.Among the intensive investigations of infusion of CAR-T cells after transplant,few focus on patients who were administered CAR-T therapy after they relapsed subsequently to UCBT.Here,we report the response rate,toxicity,and survival of CD19 CAR-T cells administered to 10 children and young adults with relapsed acute B lymphoblastic leukemia(B-ALL)after UCBT.Between April 2018 and September 2019,11 patients with relapsed B-ALL after UCBT were enrolled,including three females and eight males,the median age was 10 years(range 7-22 years)and median weight was 35.0 kg(range 21.0-72.0 kg).Patient 10 was excluded because of unsuccessful cell culture.
